Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Work In Process (2016 - 2025)

Historic Work In Process for Heron Therapeutics (HRTX) over the last 10 years, with Q3 2025 value amounting to $26.3 million.

  • Heron Therapeutics' Work In Process rose 4354.29% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 million, marking a year-over-year increase of 4354.29%. This contributed to the annual value of $27.2 million for FY2024, which is 8687.29% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Work In Process is $26.3 million, which was up 4354.29% from $26.1 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Work In Process high stood at $29.0 million for Q1 2025, and its period low was $9.0 million during Q2 2023.
  • Over the past 5 years, Heron Therapeutics' median Work In Process value was $16.4 million (recorded in 2023), while the average stood at $17.9 million.
  • Per our database at Business Quant, Heron Therapeutics' Work In Process soared by 20575.43% in 2021 and then tumbled by 5517.77% in 2023.
  • Over the past 5 years, Heron Therapeutics' Work In Process (Quarter) stood at $20.9 million in 2021, then fell by 1.01% to $20.7 million in 2022, then fell by 29.79% to $14.6 million in 2023, then soared by 86.87% to $27.2 million in 2024, then fell by 3.12% to $26.3 million in 2025.
  • Its last three reported values are $26.3 million in Q3 2025, $26.1 million for Q2 2025, and $29.0 million during Q1 2025.